Catalog No.
KDC20801
Detection method
Colorimetric
Sample type
Plasma, Serum
Assay type
Quantitative
Range
78.125 - 5,000 ng/mL
Sensitivity
33.12 ng/mL
Precision
CV<20%
Recovery
80-120%
Shipping
2-8 ℃
Stability and Storage
The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 10% prior to the expiration date under appropriate storage condition.
Alternative Names
MEDI-507, CAS: 288392-69-8
Siplizumab combination therapy with belatacept or abatacept broadly inhibits human T cell alloreactivity in vitro., PMID:37270108
Distinct association between chronic Epstein-Barr virus infection and T cell compartments from pediatric heart, kidney, and liver transplant recipients., PMID:37187296
Immunotherapy in indolent Non-Hodgkin's Lymphoma., PMID:35663281
Siplizumab Induces NK Cell Fratricide Through Antibody-Dependent Cell-Mediated Cytotoxicity., PMID:33643309
Siplizumab, an Anti-CD2 Monoclonal Antibody, Induces a Unique Set of Immune Modulatory Effects Compared to Alemtuzumab and Rabbit Anti-Thymocyte Globulin In Vitro., PMID:33262770
CD2 Immunobiology., PMID:32582179
Pharmacokinetic and pharmacodynamic study of a clinically effective anti-CD2 monoclonal antibody., PMID:31630416
Siplizumab selectively depletes effector memory T cells and promotes a relative expansion of alloreactive regulatory T cells in vitro., PMID:31319439
Phase I dose escalation study of the anti-CD2 monoclonal antibody, siplizumab, with DA-EPOCH-R in aggressive peripheral T-cell lymphomas., PMID:29032710
Novel and emerging drugs for rarer chronic lymphoid leukaemias., PMID:22483155
Safety profile of intravenous and subcutaneous siplizumab, an anti-CD2 monoclonal antibody, for the treatment of plaque psoriasis: results of two randomized, double-blind, placebo-controlled studies., PMID:20618506
Safety profile, pharmacokinetics, and pharmacodynamics of siplizumab, a humanized anti-CD2 monoclonal antibody, in renal allograft recipients., PMID:19917362
Phase-1 study of siplizumab in the treatment of pediatric patients with at least grade II newly diagnosed acute graft-versus-host disease., PMID:19671093
Safety profile and clinical outcomes in a phase I, placebo-controlled study of siplizumab in acute graft-versus-host disease., PMID:19623014
Humanized anti-CD2 monoclonal antibody treatment of plaque psoriasis: efficacy and pharmacodynamic results of two randomized, double-blind, placebo-controlled studies of intravenous and subcutaneous siplizumab., PMID:19471949
EBV-related lymphoproliferative disease complicating therapy with the anti-CD2 monoclonal antibody, siplizumab, in patients with T-cell malignancies., PMID:19293260
Regulatory T-cell recovery in recipients of haploidentical nonmyeloablative hematopoietic cell transplantation with a humanized anti-CD2 mAb, MEDI-507, with or without fludarabine., PMID:17588483
Monoclonal antibodies in the treatment of non-Hodgkin's lymphoma., PMID:17335294
The anti-CD2 monoclonal antibody BTI-322 generates unresponsiveness by activation-associated T cell depletion., PMID:15544625
Gateways to clinical trials., PMID:12949633
Effective therapy for a murine model of adult T-cell leukemia with the humanized anti-CD2 monoclonal antibody, MEDI-507., PMID:12649132
Gateways to clinical trials., PMID:12224444